Lilly Endowment awarded $230 million in 2012, mostly to Indiana groups. Its fortunes still are largely tied to the value of Eli Lilly and Co. stock, despite an effort to diversify the private foundation’s holdings.
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
Five of the six Hoosier firms that appear in the 2013 rankings slipped from their positions in last year’s list of the largest U.S. companies.
John Lechleiter has been suffering from a dilated aorta, Eli Lilly and Co. said Monday. Current CFO Derica Rice will take his place until later this summer.
The effort to launch the Indiana Biosciences Research Institute got $25 million from the Legislature, but the life sciences institutions backing the effort have set their funding sights much higher.
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
The Indianapolis pharmaceutical company left its full-year profit forecast unchanged despite a spike in first-quarter earnings. Revenue fell short of analyst expectations.
Investors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines of new products. The big pharma firms begin to report first-quarter earnings this week.
The pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have advanced its request for tax breaks to a public hearing and final consideration May 1.
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
Investor smiles about new experimental cancer drugs and an aggressive play for the animal health market in China turned to frowns after Lilly disclosed deep cuts to its U.S. sales force.
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
Lawyers for a security company being sued in the theft of $60 million worth of pharmaceuticals from an Eli Lilly and Co. warehouse in Connecticut say there's no proof the thieves used a report it prepared about security weaknesses in the building.
Fortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
A federal lawsuit contends that thieves who broke into an Eli Lilly and Co. warehouse in Connecticut three years ago and stole more than $60 million worth of drugs obtained a copy of a report that revealed weaknesses in the building's security system.
